Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940611 | 0.80 | PIM1 (0.49) | HASPINPIM1TTKPIM2JAK2 | |
| SCHEMBL9940628 | 0.79 | MAPT (0.36) | PIM1TTKPIM2JAK2JAK1 | |
| SCHEMBL29377248 | 0.76 | RPS6KB1 (0.36) | PIM1TTKPIM2JAK2JAK1 | |
| SCHEMBL1559078 | 0.76 | RPS6KB1 (0.36) | PIM1TTKPIM2JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL1560043 | 0.75 | RPS6KB1 (0.35) | PIM1TTKPIM2JAK2JAK1 | |
| SCHEMBL9940536 | 0.74 | TTK (0.38) | HASPINPIM1TTKPIM2NNMT | |
| Phosphoric Acid SCHEMBL20600153 | 0.72 | RPS6KB1 (0.33) | PIM1TTKPIM2JAK2JAK1 | |
| SCHEMBL2172072 | 0.72 | PARP1 (0.49) | DYRK1A | |
| Trifluoroacetic Acid SCHEMBL9936778 | 0.71 | L3MBTL1 (0.34) | PIM1TTKPIM2 | |
| SCHEMBL9940675 | 0.70 | PIM1 (0.43) | HASPINPIM1TTKPIM2NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | claimed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | claimed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2614065-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | HASPIN 538/4885PIM1 1/4885TTK 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.